A severe leakage of intermediates to shunt products in acarbose biosynthesis
Biosynthetic mechanism for the type 2 diabetes treatment drug acarbose is not fully revealed. Here, the authors show that shunt pathways and inefficient amino-deoxyhexose biosynthesis lead to 1-epi-valienol and valienol accumulation, and minimizing the flux to these shunt products can increase acarb...
Guardado en:
Autores principales: | Qinqin Zhao, Yuchang Luo, Xin Zhang, Qianjin Kang, Dan Zhang, Lili Zhang, Linquan Bai, Zixin Deng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0db4c8b5727345a0bbbd13552ff25ed1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Determination of the Protein-Protein Interactions within Acyl Carrier Protein (MmcB)-Dependent Modifications in the Biosynthesis of Mitomycin
por: Dongjin Leng, et al.
Publicado: (2021) -
A [6+4]-cycloaddition adduct is the biosynthetic intermediate in streptoseomycin biosynthesis
por: Kai Biao Wang, et al.
Publicado: (2021) -
MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Na Wang, et al.
Publicado: (2019) -
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
por: Rosak C, et al.
Publicado: (2012) -
Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
por: Song L, et al.
Publicado: (2021)